Rituximab versus cyclophosphamide for ANCA-associated vasculitis

Area of Science:

• Rheumatology
• Immunology
• Nephrology

Background:

• Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease.
• Cyclophosphamide and glucocorticoids have been standard treatments for decades.
• Rituximab shows promise as a potentially safer alternative.

Purpose of the Study:

• To compare the efficacy and safety of rituximab versus cyclophosphamide for remission induction in severe AAV.
• To determine if rituximab is non-inferior to cyclophosphamide in treating AAV.
• To evaluate rituximab's effectiveness in relapsing AAV cases.

Main Methods:

• A multicenter, randomized, double-blind, double-dummy, noninferiority trial.
• 197 ANCA-positive patients with Wegener's granulomatosis or microscopic polyangiitis were enrolled.
• Primary endpoint: remission without prednisone at 6 months.

Main Results:

• Rituximab (64%) met noninferiority criteria compared to cyclophosphamide (53%) for remission induction (P<0.001).
• Rituximab showed superior efficacy in relapsing disease (67% vs. 42%, P=0.01).
• Similar effectiveness and adverse event rates were observed between groups for major renal disease and alveolar hemorrhage.

Conclusions:

• Rituximab is non-inferior to cyclophosphamide for inducing remission in severe ANCA-associated vasculitis.
• Rituximab may be a superior option for patients with relapsing disease.
• The study supports rituximab as an effective and safe treatment for AAV.